SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcomaMasum Saini, Sam J. Mathew|Cell Death and Disease|2018Cited by 30
Musculoskeletal defects associated with myosin heavy chain‐embryonic loss of function are mediated by the YAP signaling pathwayAnushree Bharadwaj, Sam J. Mathew|EMBO Molecular Medicine|2023Cited by 12
Zeb1 and Tle3 are <i>trans</i> ‐factors that differentially regulate the expression of myosin heavy chain‐embryonic and skeletal muscle differentiationPankaj Kumar, Sam J. Mathew|The FASEB Journal|2023Cited by 8
Tumor suppressor candidate 1 (TUSC1) drives oxidative phosphorylation and tumor cell death in colorectal cancerJanvie Manhas, Jayanth Kumar Palanichamy, Sagar Tyagi et al.|APOPTOSIS|2026Cited by 0